Search results
Results from the WOW.Com Content Network
Chlormadinone acetate (CMA), sold under the brand names Belara, Gynorelle, Lutéran, and Prostal among others, is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy, as a component of menopausal hormone therapy, in the treatment of gynecological disorders, and in the treatment of androgen-dependent conditions like enlarged prostate and prostate ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
[2] [3] [4] It was the first product for use in menopausal hormone therapy containing CPA to be marketed [3] and is available in more than 40 countries. [2] Femilar, which is an estradiol-containing birth control pill, contains 1 to 2 mg estradiol valerate and 1 to 2 mg CPA, and has been approved for use in Finland since 1993. [5] CPA alone has ...
A single oral dose of 10 mg MPA has been found to result in peak MPA levels of 1.2 to 5.2 ng/mL within 2 hours of administration using radioimmunoassay. [ 202 ] [ 203 ] Following this, levels of MPA decreased to 0.09 to 0.35 ng/mL 12 hours post-administration.
Rasagiline inhibits platelet MAO-B activity with single doses by 35% one-hour after 1 mg, 55% after 2 mg, 79% after 5 mg, and 99% after 10 mg in healthy young people. [ 1 ] [ 55 ] [ 2 ] [ 54 ] With all dose levels, maximum inhibition is maintained for at least 48 hours after the dose.
Methylergometrine is sometimes used for both prevention [6] and acute treatment [7] of migraine. It is an active metabolite of methysergide. [8] In the treatment of cluster headaches, methylergometrine has been initiated at a dose of 0.2 mg/day, rapidly increased to 0.2 mg three times per day, and increased to a maximum of 0.4 mg three times per day.
Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100 mg/day, in 5 of 8 (62.5%) at 200 mg/day, and in 6 of 9 (66.7%) at 400 mg/day, relative to none of 12 controls. [134] [135] The severity of gynecomastia with spironolactone varies considerably, but is usually mild. [110]
The organization established an ADI (Acceptable Daily Ingestion) of 0-0.01 mg/kg of body weight, because of the NOAEL (No Observed Adverse Effect Level) of 1.1 mg/kg of body weight per day for erythrocyte damage and secondary splenic and liver changes. This was established in a 2-year study in rats.